The global automated and closed cell therapy processing system market size was exhibited at USD 1.9 billion in 2022 and is projected to hit around USD 15.63 billion by 2032, growing at a CAGR of 23.46% during the forecast period 2023 to 2032.
Key Pointers:
- North America generated more than 46.9% of the revenue share in 2022.
- By workflow, the expansion segment dominates the market and captures more than 35.2% of the revenue share in 2022.
- By workflow, the apheresis segment is projected to witness remarkable growth between 2023 and 2032.
- By type, the non-stem cell therapy segment dominates the market and generated more than 60.1% of the revenue share in 2022.
- By scale, The Research and development (R&D) scale segment captured more than 70.8% of the revenue share in 2022.
- By scale, the commercial scale segment is expected to register remarkable growth from 2023 to 2032.
Automated and Closed Cell Therapy Processing System Market Report Scope
The growing popularity of regenerative medicines & cell therapies coupled with a range of benefits offered by automation technologies for the development of these therapies is expected to propel the market growth. In addition, the growing integration of software technologies and advanced therapy development processes is also projected to boost the market. Furthermore, rising investments by bio manufacturers for the development of cellular therapy products through rounds of series funding are anticipated to offer lucrative opportunities to or the market.
In recent years, there has been massive growth in clinical trials associated with advanced therapies. This growth has led to an increase in demand for advanced and automated technologies to achieve high throughput and yield. This can be attributed to the fact that automated and closed systems offer better cell handling capabilities and reduce the possibility of errors during bioprocessing.
The availability of a range of systems to offer both automated integrated workflow solutions and partial automation is expected to spur the adoption rate in the space. Furthermore, the system also enables continuous monitoring of controlled therapy processing, which is being conducted for the development of new therapeutic platforms. In addition, integrated intelligent algorithms facilitate high precision. Market players are actively engaged in the development of infrastructure to leverage the production of automated systems.
For instance, in June 2021, the collaboration of Lonza and Cell Point announced its plan to utilize the Cocoon platform for the development of T-cell-based therapies. The project is being conducted to provide a proof of concept for Point-of-Care (POC) production to optimize the supply chain operations. Also, as automated systems can enhance analytical testing and facilitate quality control, the systems are expected to witness substantial acceptance during the forecast period.
Some of the prominent players in the Automated and Closed Cell Therapy Processing System Market include:
- Lonza
- BioSpherix
- Cellares
- Sortorius
- Cytiva
- ThermoGenesis Holdings Inc
- Thermo Fisher Scientific Inc
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Automated and Closed Cell Therapy Processing System market.
By Workflow
- Cryopreservation
- Fill-finish
- Separation
- Expansion
- Apheresis
- Others
By Type
- Stem Cell Therapy
- Non-stem Cell Therapy
By Scale
- Commercial Scale
- R&D Scale
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Request Customization
Get a Sample
Get a Sample
Request Customization